LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration ...
EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM: ADLR) today announced that the results of a Medication Use Evaluation (MUE) conducted by clinical pharmacists and surgeons at the Moses Cone ...
Entereg Approved for Expanded Use After GI Surgery Cubist Pharmaceuticals announced that the FDA has approved the use of Entereg (alvimopan) to accelerate the time to upper and lower gastrointestinal ...
Cubist Pharmaceuticals announced that it has submitted a supplemental new drug application (sNDA) to the FDA requesting approval for the use of Entereg (alvimopan) to accelerate GI recovery following ...
EXTON — More than 500 hospitals have enrolled in Adolor Corp.’s Entereg access support and education program since the product was launched in June. “We are delighted with the interest of the hospital ...
US biotechnology group Adolor saw its stock value almost chopped in half yesterday, as a mixed bag of clinical results from two late-stage trials of its key candidate Entereg – which it is developing ...
The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the mu-opioid receptor antagonist alvimopan (Entereg, Cubist Pharmaceuticals). The FDA originally ...
GlaxoSmithKline and partner Adolor will have been cheered yesterday after a US Food and Drug Administration advisory panel narrowly voted 9-6 that its mu-opioid receptor antagonist Entereg’s ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NAS: CBST) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results